header logo image


Page 820«..1020..819820821822..830840..»

Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction…

November 24th, 2019 11:49 pm

OBJECTIVES:

Stem cell therapy is a promising approach in the treatment of acutemyocardial infarction(AMI). Mesenchymal stem cells (MSC) from bone marrow (BM-MSC) and adipose tissue (AT-MSC) are attractive and feasible for preclinical and clinical trials. In this study, we compared the therapeutic potential of BM-MSC and AT-MSC in repairing the hearts of rats with isoproterenol (ISO)-induced AMI.

Forty-two female rats were assigned into two groups; the optimization and the experimental group. The optimization groups were further subdivided into control group and the AMI induced group (using ISO). The experimental group was subdivided into AMI+cell-free media injected in the tail vein, AMI+BM-MSC, and AMI+AT-MSC groups treated with the intravenous injection of their respective cell types. Twenty-eight days after induction, electrocardiogram (ECG) was performed, and heart tissue samples were collected for histological assessment and cells tracing.

MSC therapy repaired cardiac functions shown by the restoration of ST segment, QT and QRS intervals in the ECG when compared to the AMI group. Infarct area was significantly decreased, and cardiac tissue regeneration signs were shown on histopathological examination.

Both MSC sources proved to be equally efficient in the assessed parameters.

See the original post:
Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction...

Read More...

Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,…

November 24th, 2019 11:49 pm

In the forecast period, the global stem cell therapy market is expected to generate revenue about 978 million USD in 2027, growing at a CAGR of 20% by 2019-2027.

Stem cells are found in all human beings, from the initial stages of human growth to the end of life. All stem cells are beneficial for medical research; however, each of the different kinds of stem cells has both limitations and promise. Embryonic stem cells that can be obtained from a very initial stage in human development have the prospect to develop all of the cell types in the human body. Adult stem cells are found in definite tissues in fully developed humans. Stem Cell Therapy Market are basic cells of all multicellular animals having the ability to differentiate into a wide range of adult cells. Totipotency and self-renewal are characteristics of stem cells. However, totipotency is seen in very early embryonic stem cells.

Report Consultant has added a new report to its database that qualifies an expressive and professional look into this market. The report is titled a Global stem cell therapy Market. Thus, the report scrutinizes the present-day environment of the market in order to generate a comprehensive understanding of the future plans of the market. Porters five and SWOT analysis have been utilized to scrutinize the Global stem cell therapy Market.

Grab Eye-Popping Black Friday Deals on this Report @

Top Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, and Takeda (TiGenix)

The report provides a brief timeline for each segment of the stem cell therapy market. Key drivers and restraints impacting the market segments are also demonstrated precisely. It also helps in determining reasons for the progress of certain segments over others in the looming years. The overall market is also segmented on the basis of geography in the United States, Europe, India, Japan, China, and Southeast Asia. The geographical segmentation provides a distinct assessment of the factors supporting these regions, the favorable regulatory policies, and the impact of the political frameworks.

The global stem cell therapy market report is integrated considering the primary and secondary research methodologies that have been collected from reliable sources intended to generate a factual database. The data from market journals, publications, conferences, white papers and interviews of key market leaders are compiled to generate our segmentation and is mapped to a fair trajectory of the market during the forecast period.

Get Sample Copy of Report @

https://www.reportconsultant.com/request_sample.php?id=4868

Stem Cell Therapy market On the basis of product,

Stem Cell Therapy market On the basis on the Applications,

In This Study, The Years Considered To Estimate the Size Of stem cell therapy Market Are As Follows:

If you have any special requirements, please let us know and we will offer you the report as you want.

See the article here:
Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,...

Read More...

Decoding the building blocks of life: bit bio races toward a sustainable source of human cells – Proactive Investors UK

November 24th, 2019 11:49 pm

The ability to turn human cells into anything we want sounds like the stuff of science fiction. But one Cambridge biotech says it's cracked the code

A sustainable source of human stem cells is one of the holy grails of modern medicine.

With applications as broad as re-growing failed organs, fighting cancer, and stopping animal testing, stem cell therapy is predicted to be worth US$35bn by 2023.

Now, Cambridge startup bit bio, has a new approach to re-coding skin cells from adult humans, and rewinding the clock to give them the power of stem cells, and then turn them into whatever we want them to be all without the controversial involvement of human embryos.

This, says neurosurgeon and founder Dr Mark Kotter, will democratise stem cells, so that anyone can use them, at any time.

The private sector is already placing big bets on the technology, with start-ups in the space raising as much as US$16mln in recent funding rounds.

Kotter says that our inability to produce enough human stem cells to match our need puts troubling limits on research and drug development.

In drug discovery, the biggest bottleneck is the mismatch between animal models and animal cell lines used for drug discovery, and then human setting used in the clinical trial, he explains.

Around 3% of new drugs make it all the way through trials and to market, he says, and the biggest reasons treatments tend to fail in clinical study is that they are either toxic to humans, or they dont work.

The only solution is to bring the human element back to the early stages, says Kotter.

If new therapies were tested on human tissue first, it would reduce or even bypass the need to test on animals, as well as speeding up development.

Kotter founded bit bio, formerly known as Elpis BioMed, in 2016, in addition to startup Meatable, which produces meat by growing cultures in the lab, rather than rearing animals for the table.

The time is now for bit bio, because what it is doing has only been possible since a Nobel Prize-winning discovery twelve years ago, which turned the world of stem cell research upside down.

Kyoto University researcher Shinya Yamanaka proved that it was possible to take a mature human skin cell and reprogram it to be like the stem cell of an embryo.

Until this revelation, stem cell research had been dogged by controversy and expense, as scientists had to use human embryos and umbilical cords as a source of stem cells, and then simulate complex conditions inside the womb in order to make them develop into the cells they desired.

One big problem in early cell reprogramming was that stem cells are incredibly alert to invading DNA and silences any foreign material it detects.

This meant that past attempts run a different program inside a cell often failed, because the cell destroyed it.

What happened next was a moment of "serendipity" in the lab, says Kotter.

Through trial and error, bit bio found they could use certain safe harbours where information is protected within cells, to stop theinterference.

By taking the genetic switch for gene silencing and placing it inside a safe harbour, and then separately running the new cell program inside another safe harbour, scientists found they could override gene silencing in order to change the cell type.

This approach is what Kotter says makes bit bio unique.

The lab can produce up to a kilogram of human cells now, and its tech platform opti-oxhas also proved that it can generate two human cell types with 100% accuracy.

Kotter says that now the range of cells able to be produced matters more than the quantity.

The company is now focused on discovering what separates one type of cell from another, which Kotter says will allow the firm to decode the building blocks of life.

To this end, bit bio is using machine learning to analyse the differences between every type of human cell, from bone marrow cells to liver cells, and create a reference map for all the different types.

Once the research is complete, the company hopes it willbe able to generate any type of human cell, at scale, and with ultimate precision.

Preparations are underway for a Series A funding round, and Kotter says that he is determined not to sell the business, having already rejected offers from would-be buyers.

Bit bio though is in an area hot with competition, which moves quickly.

A US$16mln Series A mega funding round was recently announced in October by another Cambridge start-up, Mogrify, which is hoping to master direct cell reprogramming and turn blood cells straight into brain cells, or any other type.

Mogrify uses big data to identify the small molecules needed to convert, maintain and culture a target cell type.

While both companies were finalists in the 2018 Cambridge Startup of the Year award, bit bio was the one to scoop the prize.

One aspect that separates the two companies is that Mogrify uses its technology to turn cells directly into other cell types, rather than using it to rewindto the stem cell phase, which is when cells can reproduce very quickly,

Kotter says that this stem cell phase focusis whatallows bit bio to havea stable supply of human cells.

If bit bio completes a similar, or even bigger, fundraise, it could advance the fledgling firm from seed to stem, in its attempt to stabilise a production line for essential cell technology.

Continue reading here:
Decoding the building blocks of life: bit bio races toward a sustainable source of human cells - Proactive Investors UK

Read More...

Almost 27000 persons with HIV in Cuba – OnCubaNews

November 24th, 2019 11:48 pm

In Cuba there are 26,952 persons infected with the HIV/AIDS virus until the end of November, according to data released this Thursday by the islands National Center for Health Promotion and Education (CNPES).

Among those diagnosed, the most affected are transsexual women, with 19.7%; men who have sex with other men (MSM), 5.6%; and people who practice transactional sex (in exchange for objects, money or privileges), which are 2.8%.

The Cuban provinces that show the highest incidence of contagion are Havana, the central Cienfuegos and the eastern Las Tunas and Guantnamo, said CNPS Deputy Director Otto Pelez, cited by the state-run Agencia Cubana de Noticias (ACN) news agency.

The islands public health authorities highlight the control in maternal-infant transmission in children under 14, in heterosexual people, as well as the early detection of the disease, among the positive results of the Cuban program to prevent the spread of the virus, which is recognized by international organizations.

At the close of 2018, about 25,494 persons with HIV/AIDS had been detected in the Caribbean country, and more than 2,200 of them were new cases.

At that time 80% (20,446) were men and the rest (5,048) women, aged between 15 and 49, 74%, according to data from the Ministry of Public Health (MINSAP) collected by state media.

Ms de 2,200 nuevos casos de VIH en Cuba en 2018

In 1985, four years after the disease was discovered, the first case of HIV/AIDS was detected in Cuba in a man who had spent two years in Mozambique, Africa. Since then, the number who have contracted the virus is more than 30,000, of which a part died.

In the early days after the onset of the epidemic in the country, the diagnosed persons were admitted to health centers where they received treatment and were kept in isolation, with exceptional outings, in order to avoid the transmission of the virus.

On the island, patients receive a free treatment of five locally produced retrovirals combined with other imported ones. The objective of this therapy is to keep the levels of the AIDS virus low in blood and control its multiplication, which means that the patient has no complications and remains stable, according to the specialists.

Last March, pre-exposure prophylaxis pills (PrEP) started being given out in Cuba to prevent the spread of HIV in healthy people, a relatively new treatment in the Americas that is estimated to reduce the probability of contracting the virus by 90%.

In addition, since 2017 Cuban scientists have been testing the TERAVAC-VIH vaccine, developed at the Center for Genetic Engineering and Biotechnology in Havana and designed to reduce the viral load of patients with the virus and improve the quality of life of the patients.

EFE / OnCuba

Read the rest here:
Almost 27000 persons with HIV in Cuba - OnCubaNews

Read More...

Microbes ‘set to be an integral part of agriculture over the next 20-30 years’: Joyn Bio – FoodNavigator.com

November 24th, 2019 11:48 pm

The acceptance of the microbiome diet as a means of achieving gut health among consumers could pave a path for a shift in attitude towards GM food, according to Michael Miille CEO at Joyn Bio.

Proponents of GM food contend that genetic engineering can help us find sustainable ways to feed people. One proponent is the US start-up Joyn Bio, a joint ag-tech venture between synthetic biology company Ginkgo Bioworks and pharma giant Bayer, which was formed in 2017 with a $100 million Series A round coming from its two parent companies.

Joyn Bio is attempting to engineer microbes that can provide plants with biological nitrogen fertilizer, thus decreasing the environmental impact of agriculture.

By engineering microbes it can eliminate the need for synthetic fertilizers, which have boosted crop yields over the past century but in the process have harmed soil health and caused environmental ills. Runoff from excess nitrogen fertilizer into rivers and oceans has created a dead zone of toxic algae in the Gulf of Mexico the size of New Jersey, for example.

Joyn Bio is headquarted in Boston. Its testing facility in California focuses on the genetic modification of the colonies of bacteria that make up crops microbiomes. It can then engineer those microbes to produce specific proteins as possible alternative to chemical fertilizers and other chemicals.

Any product is unlikely to be ready for market before 2020. Neither will any product be offered in Europe, where regulations do not currently permit engineered microbial products as produced by Joyn Bio (its current focus is on offering its solution to growers in the US, Brazil and India).

It believes nevertheless that it offers a potential global solution to the challenges facing the food industry. Its goal is to engineer microbes to reduce the amount of industrial nitrogen fertilizer needed to grow crops like corn, wheat, or rice, to dramatically decrease the water pollution, fossil fuel used and greenhouse gases produced by agriculture today.

"What we were really launched around was nitrogen fixation and recognising the environmental impact both in production and in application of the synthetic nitrogen fertilisers, which is not sustainable, then at the same time trying to come up with a solution,explained Miille.

Growers, he believes, are in desperate need of innovation and additional solutions given all the things they are confronting.Joyn Bio claims it can help farmers increase yield by promoting stronger plants and better nutrient uptake, ultimately contributing to the transformation of agriculture towards a more sustainable future.

How exactly does it all work? Our product would be a microbe that associates with the plant and is delivered as a seed treatment, said Miille.

Image the microbe as a trillion little FedEx trucks running all over the plant delivering cargo, he says. That cargo then takes nitrogen from the air, converts it into the nitrogen that the plant needs, and then gives it to the plant.

Its very similar to what happens in a soy bean plant naturally via evolution, but the soy and wheat plants never did that.

All this can allow a grower to reduce their fertilizer input by 30-40%, thus saving the grower money and allowing them to benefit from an environmental standpoint.

The process could potentially be used to make food more nutritious too. "You could use the microbes to signal the plant to potentially produce more of its nutritious part - there are number of nutrition enhancements that you can engineer. It's not our initial focus because it's a little more challenging but [improved nutrition] is certainly something people are looking at across the whole food spectrum today.

GM foods have something of a toxic legacy with European consumers, however, of which Miille is well aware. His solution to this challenge is simply to be straight with people. The problems of the past came about because companies such as Monsanto failed to be, he said. "Were trying to learn from that. I think its really critical to be transparent with consumers. Well want them to know we have these engineered microbes and here's what they did.

If crops produced via engineered microbes are used to grow something viable then people will accept it, he believes. Take the papaya industry in Hawaii, he noted, which was saved by GMO technology. "The same thing is going to happen with the US chestnut industry. There are going to be more examples of a pest or diseases that will threaten to wipe something out and the solution is biotechnology. And when you can save something when its that dramatic a benefit and you can communicate that to consumers, they get it.

He continued: For those of us on the science, technology and innovation side, the important thing is to understand how critical it is to engage with consumers and be transparent with them. The other side of the equation is to be able to articulate the benefit. If the benefit is that you either have strawberries or you don't, people will get that.

"Another thing in our favour is that peoples opinions and concerns about chemicals are probably at an all-time high.

The growth in popularity of the microbiome diet among consumers is another potential factor in Joyn Bios favour. If consumers now accept that the microbes in our gut play a critical role in overall health, whats not to stop them accepting the importance microbes could potentially have in agriculture?

More people than ever are taking probiotics because it improves gut health, said Miille. The next step is to say to consumers that microbes are part of the solution and all we've really done is taken this microbe and selectively optimised it for its particular purpose. These kind of discussions, he said, will get people to accept that microbes are going to be an integral part of agriculture over the next 20-30 years.

Originally posted here:
Microbes 'set to be an integral part of agriculture over the next 20-30 years': Joyn Bio - FoodNavigator.com

Read More...

‘A leap of faith’: FDA just approved the first pig-to-human tissue transplant – The Daily Briefing

November 24th, 2019 11:48 pm

FDA for the first time has approved an experiment that involves temporarily transplanting pig tissue into humans, a move that experts say could lead to further developments in animal-to-human donations, Emily Mullin reports for Medium's "OneZero."

CRISPRand 7 other technologies that could transform health care

Each year in the United States, the waiting list for organ transplants grows and outpaces the number of available donations. And due to strict donor criteria, skin is also difficult to acquire, Mullin reports.

The new FDA-approved trial will focus on skin transplanted from pigs to humans.

Usually, second and third-degree burns are treated with human skin grafts to protect the wounds and help fight off infection. But researchers at biotech company XenoTherapeutics have genetically engineered miniature pigs to allow for use in humans. The skin, called Xeno-Skin, is made from living pig tissue.

So far, the Xeno-Skin has been transplanted to one patient who received a five-by-five centimeter piece of pig skin as well as human skin grafts. Five days after the transplant, doctors removed both skin grafts and replaced them with permanent grafts from the patient's thigh. The donor pig skin healed as well as the human skin graft, according to doctors involved in the trial. The patient also did not experience any adverse reactions to the graft.

Now, as part of the FDA-approved trial, Xeno-Skin will be transplanted as temporary skin grafts to five more burn victims at Massachusetts General Hospital. The grafts will be removed once the patients' skin grows back.

The experiment is the first of its kind to be approved by FDA, Mullin reports.

XenoTherapeutics is also developing nerves in the genetically engineered pigs that could be transplanted into people with nerve damage from accidents. The clinical trial for the new treatment will likely begin next year, Mullin reports.

In the past, donations from animals to humans, also called xenotransplantation, have almost always failed, Mullin writes, with common issues including patients experiencing an immune response to the donation or the transmission of an animal virus to the human recipient. Surgeon Keith Reemtsmain the 1960s transplanted chimpanzee kidneys into humans, but most of the transplants were rejected or became infected within a few weeks. And in 1984, a baby called "Baby Fae," received a heart transplant from a baboon, but died within a month.

After transplants from apes and monkeys failed, doctors started to consider pigs as potential human donrs, Mullin reports. "The reasons are largely practical," Mullin writes. "For one, pigs take only months to grow to a size suitable for organ donation, unlike monkeys, which require 10 to 15 years. Pig organs are also closer in size to human ones."

When it comes to skin transplants, while dead, processed pig skin is already used for wound dressing, living pig tissue had never been used in humans, Mullin reports. To prevent rejection, scientists used genetic engineering to eliminate molecules found in pigs that would trigger an immune system reaction in humans. Researchers also used the gene-editing tool CRISPR to remove a group of viruses found in pigs that are considered an infection risk for human donation recipients.

While temporary pig skin grafts are much more low risk than transplanting major pig organs into humans permanently, the successful skin graft transplant further demonstrates that "the risk" of xenotransplants "is manageable," according to Megan Sykes, director of the Center for Translational Immunology at Columbia University. "The fact that the FDA allowed this [pig skin] trial reflects that thought as well."

While xenotransplants are often used as bridge transplants, or temporary transplants that are designed to keep patients alive for a period of time before they receive a transplant from a human donor, Muhammad Mohiuddin, director of the cardiac transplantation program at the University of Maryland School of Medicine who has led research on pig transplants, believes that organ xenotransplantation might evolve enough to become a longer term solution. "[O]nce we have an ideal pig available and it survives for a longer period of time, there will not be a need to replace that organ," he said.

But convincing the public that pig transplants are safe might prove to be more difficult, he added. "If you tell someone, 'We want to put a pig heart in you,' there would probably be quite an uproar," Mohiuddin said. "If this trial is successful, that will pave the way for other types of transplantations, like kidneys, hearts, lungs, or livers."

While these types of transplants might not happen for another few decades, Ardehali said the field is getting closer. "Are we about to embark on a new chapter? I don't know the answer to that. This requires a significant leap of faith" (Mullin, "OneZero," Medium, 11/11).

Read this article:
'A leap of faith': FDA just approved the first pig-to-human tissue transplant - The Daily Briefing

Read More...

Engineering RNA Binding Proteins to Improve Human Health – Advanced Science News

November 24th, 2019 11:48 pm

Share

Share

Email

The central dogma of biology describes the flow of genetic information from DNA to RNA to proteins. While RNA was originally believed to be a carrier of genetic information, subsequent work has shown something completely different: RNA is now known to have function independent of proteins, with a rich layer of regulatory networks. In fact, a large amount of the RNA present in a cell does not actually make proteins. This increased appreciation and understanding has led to many fascinating mechanistic insights into RNA and its role as a central player in cellular regulation and human disease.

Helping to facilitate RNA function are a large number of proteins that can bind to and regulate RNA. These RNA-binding proteins, or RBPs, number in the thousands and are made up of many different independent modular segments similar to a childs set of building blocks. In much a similar fashion, these blocks or domains provide nature with a way of mixing and matching different domains to generate new functions. In recent years, researchers have sought to learn from biology and use these building blocks to engineer new proteins with unique functions that are helpful in research and human health. In a recent study published in WIREs RNA, Professor Andrew Berglund and his colleagues describe recent advances and challenges in engineering RBPs.

Engineering [RBPs] is a powerful tool for researchers to probe the mechanisms of RNA processing pathways says Dr. Andrew Berglund, the newly appointed Director of the RNA Institute at the University at Albany. It is also a promising approach for the development of novel therapeutic molecules.

Potential targets for this approach are abundant as many human diseases have a strong RNA or RBP component, including the most common cause of muscular dystrophy and amylotrophic lateral sclerosis. For therapeutic purposes, engineered RBPs can be designed to replace a defective cellular RBP or bind and destroy toxic RNA. RBPs can also be engineered with new functions and/or targets as well as being marked or tagged so that the researcher can follow their progression within the cell, like a GPS tracker for RNA. The modular nature of RBPs makes it possible to add or mix function to suit the goal of almost any researcher.

In their study published in WIREs RNA, the research team highlights two specific types of RBDs domains, PPR and PUF domains, which are the most straightforward choice for protein engineering. Researchers have studied these domains, understand how to design them to bind specific RNA sequences, and even have websites that can be used to design a domain to target your RNA of choice. Not all RBP engineering is this straightforward, with most researchers having to consider other factors such as the type of linker between domains, where in the tissue or the cell that protein must go, and how to attach other domains to give the engineered protein function.

Ultimately, as more functions of RNA are discovered and more diseases are linked to RNA misregulation, the greater the importance will be for designing, engineering, and testing novel RNA binding proteins. Somewhere in a jumble of RBP building blocks may lie the key to unlocking the next big discovery on RNA and potentially the next generation of therapeutics to improve human health.

Kindly contributed by the authors.

See original here:
Engineering RNA Binding Proteins to Improve Human Health - Advanced Science News

Read More...

Podcast: From Jurassic Park to woolly mammoths is it right to bring back extinct species? – Genetic Literacy Project

November 24th, 2019 11:48 pm

Geneticist Kat Arney takes a look at the science of de-extinction, asking whether its feasible or even ethical to bring species back from the past.

In 2003, Spanish researchers used cloning techniques to bring back the recently extinct bucardo (a type of mountain goat), only for the first cloned animal to die within minutes of birth.Other scientists are using genetic engineering techniques to stitch together the genomes of extinct species like passenger pigeons and woolly mammoths with their modern-day relatives.

Could these tools ever be used to bring back the biggest animals of them all, the dinosaurs? And is all this effort really worth it, or should we be focusing on conserving the species we already have on Earth?

Arney also investigates the history of one of the most famous diagrams in biology the Tree Of Life which Charles Darwin famously drew in 1837 to illustrate the evolutionary relationships between species.

Todays trees much more complex, bushy thickets, informed by modern genomics. But all this data brings a new challenge: deciding what counts as a species in the first place.

Full transcript, credits and show notes are available here.

Genetics Unzipped is the podcast from the UK Genetics Society, presented by award-winning science communicator and biologist Kat Arneyand produced byFirst Create the Media.Follow Kat on Twitter@Kat_Arney,Genetics Unzipped@geneticsunzip,and the Genetics Society at@GenSocUK

Listen to Genetics Unzipped onApple Podcasts(iTunes)Google Play,Spotify,orwherever you get your podcasts

Follow this link:
Podcast: From Jurassic Park to woolly mammoths is it right to bring back extinct species? - Genetic Literacy Project

Read More...

How synthetic biology will allow us to redesign humans ‘from the ground up’ – Genetic Literacy Project

November 24th, 2019 11:48 pm

Just as physics and chemistry have given humans power over the world of the inanimate, biology is giving us the ability to engineer living systems, from viruses and bacteria to animals and people.

Which is why [Wired co-founder Jane] Metcalfe thinksdesigncould be the next big thing in medicine.

Well combat disease and improve human health by designing biological systems from the ground up. We can design embryos. We can edit genes in humans. We have synthetic biology. And so we really are looking at designing future humans, Metcalfe said.

The ultimate goal is writing whole human genomes from scratch, and [Andrew] Hessel cofounded Genome Project-write (GP-write) to convene the worlds top synthetic biologists to do just that.

There are obviouslybig hurdles that still need clearingincluding software that can make design more accurate and efficient and DNA synthesis tools that assemble longer base-pair sequencesand Hessels group recently published a paper outlining the challenges.

Literally in 10 years weve gone from making proteins synthetically to making a eukaryote, he said. As soon as we can start making whole chromosomes, well, weve only got 23 of them.

Read full, original post: Why Designing Our Own Biology Will Be the Next Big Thing in Medicine

Read more:
How synthetic biology will allow us to redesign humans 'from the ground up' - Genetic Literacy Project

Read More...

Collapse in diversity threatens food security, seed rescuer says – The Age

November 24th, 2019 11:48 pm

"Theres been an enormous collapse in diversity," said Mr Blazey, the founder of gardening business The Diggers Club, which his family donated to the charity Diggers Foundation in 2011. He will also talk about the threat to food security at an event at Camperdown's Pocket City Farms on Sunday.

The number of seeds owned by the public had shrunk since genetic engineering was introduced in the early 1980s, Mr Blazey said.

First grown in 1802, the "lazy housewife" bean was one seed away from being lost forever, when it was propagated by The Diggers Club. The heirloom variety is now sold as a good bean for cooks and gardeners of any gender.

He started rescuing heirloom seeds 25 years ago, including the stringless bean, which was down to its last seed - in Germany - and sent to Australia. Since then, the world had lost about 60 per cent of vegetable varieties while the big companies such as Monsanto sold hybrids, he said.

"Thats a serious problem but most people dont see it. When you are buying a tomato, it is a hybrid and it won't be true to type [if you try to reproduce it]," he said. It also doesn't taste as good.

"If pestilence and climate change force us into disaster, we will have to ask Monsanto [recently taken over by Bayer] if we can grow [its] seeds and collect them.

"It is a disaster scenario, which nobody understands. Most of us don't realise we have lost complete control of seed supply," Mr Blazey said.

Five colour silverbeet, a very old variety, now sold by The Diggers Club.

The Grow It Local Festival and its website were started to encourage people to grow their own food, said co-founder Darryl Nichols, who also started the Garage Sale Trail 10 years ago.

There's also some "crowd farming": connecting locals who know how to garden with those who don't. Hundreds of people have registered their gardens, some running classes, including Composting 101, while others have offered advice and unused garden space.

When one of the site's Perth members offered a "seven-course plant-based patch-to-plate degustation", 14 strangers turned up, Mr Nichols said.

Like the Pocket City Farms, which is encouraging gardens in unused urban spaces, the site's members are growing vegetables wherever they can, horizontally and vertically.

In Bondi Junction, Tina has the beginning of a banana grove, with plans to fill up the nature strip with vegetables and ornamentals. In Killara, Mike is growing chili in his 15-square-metre back-garden. In Randwick, Jess and Andrew are "challenging the concept that you cant grow much in a concreted backyard". A woman is growing herbs on a vertical pallet on the verge to share with her neighbours.

It is a similar concept to The Diggers Club, which sells nearly 700 seed varieties, many heirloom, some brought to Australia by members when they migrated.

Different varieties of potatoes. Credit:David Cavanaro.

They include the pumpkin ironbark, which was down to 10 seeds a few years ago and unavailable anywhere else in the world. Reg, a market gardener, passed on seeds to two old heirloom varieties, red odourless onion and a carrot called "western red" before he died.

The number of vegetable seeds has shrunk to a fraction since 1900, according to this chart by Diggers Club. Credit:Clive Blazey

See the article here:
Collapse in diversity threatens food security, seed rescuer says - The Age

Read More...

Exhibition explores a brave new world – Griffith News

November 24th, 2019 11:48 pm

A thought-provoking new exhibition by world-renowned artist Bonita Ely has opened at Griffith University Art Museum.

Bonita Ely: Future Tense explores dystopian futures wrought by environmental degradation and genetic engineering.

The major survey exhibition brings together several of Elys major works imagining an impossible future where nature has adapted with the assistance of science, and flourished despite the devastating effects of pollution and climate change.

Shown in Australia for the first time since its debut at documenta14 in 2017, Plastikus Progressus 2017/19 parodies natural history displays. Set in 2054, it features genetically-engineered creatures that consume plastic and, in the process, clean up our mess in the streets, oceans and rivers. The installation includes a new section examining the plastic pollution of the Brisbane River.

We Live to be Surprised 1989/2019 is Elys latest installation of snabbits half snail/half rabbits. Engineered as a food source for an over-populated planet, these creatures have evolved into an ominous feral monoculture.

The exhibition also includes a major 1973 painting by Ely, The Locust People, which shows Elys interest in environmental issues since the earliest years of her practice.

Director of Griffith University Art Museum Angela Goddard, who curated the exhibition, said Ely was a fascinating artist whose practice blurred the lines between art and science.

I like her intuitive way of working and projecting ideas, and how she imagines the future and how we might adapt to it, she said.

Bonita is a major figure in contemporary art and her work has great currency, as evidenced by both installations having recently been shown in EuropePlastikus Progressus in Poland and We Live to be Surprised in the UKwe are fortunate to be able to see these works here in Australia.

Griffith University Art Museum acknowledges the generosity of exhibition partners Lock, Stock and Barrel, Shut the Gate Wines and Solver Paints.

The exhibition runs until 8 February 2020 at Griffith University Art Museum, South Bank.

Read more:
Exhibition explores a brave new world - Griffith News

Read More...

The religious polarization of India – indica News

November 24th, 2019 11:48 pm

Justice Markandey Katju-

Although the Constitution of India declares India to be a secular country, the ground reality is very different. In recent years, particularly after the Hindu right wing Bharatiya Janata Party ( BJP ) came to power in 2014, Indian society has been considerably polarized on religious lines.

Consider the following facts :

It is clear that in recent years polarization of Indian society on religious basis has witnessed an exponential upsurge. Earlier too there was communal feeling, but it was largely latent, erupting only on occasions. Now under BJP rule from 2014 it has become open, virulent. and continuous. What is the cause?

Some people say that it is because of reaction among Hindus who were earlier suppressed due to appeasement policy of Congress towards Muslims who were treated as a vote bank. Others say that Muslims are inherently fanatics and bigots, who often resort to terrorism, etc. But what is the truth?

The truth is that 99% of all people, whether Hindu, Muslim, Christian, Sikh, Jain, Parsi or Buddhist are good people. Most Muslims, like most Hindus, are peaceful, upright and law abiding. So it is absurd to say that all, or even most, Muslims are bigots and terrorists.

In fact there was no communal feeling before 1857, as I have explained in my article The Truth about Pakistan published in the Pakistani newspaper The Nation some years back. Before 1857 Hindus and Muslims lived harmoniously, Hindus used to participate in Eid and Muharram, and Muslims in Holi and Diwali.

Communalism was artificially created after suppressing the 1857 Mutiny ( in which Hindus and Muslims fought together against the British ) by the British rulers as part of their divide and rule policy ( see BN Pandes History in the service of Imperialism online ), and this was continued even after Independence, but now it has increased exponentially.

There are two reasons for the recent upsurge in communal polarization in India, one internal, and the other external. Let me explain

Internal causes of polarization

The Congress Party, by its Muslim appeasement policy (to get Muslim votes ) created a strong reaction among many Hindus, who though forming 80% of the Indian population, felt they were being ignored, and all the Congress cared for was the 15% Muslims. This naturally created a backlash, which helped the BJP to come to power in 2014. Of course, the scandalous corruption by most Congress leaders and Modis vikas slogan also helped.

However, now the Indian economy is tanking, with huge dip in GDP, manufacturing sector, IT, real estate etc. on the rapid decline, and record unemployment as admitted by National Sample Survey, a Govt of India organization ( 12 million Indian youth are entering the job market every year but jobs are shrinking ), child malnourishment ( every second Indian child is malnourished, according to Global Hunger Index and UNICEF ), 50% Indian women anaemic, farmers suicides ( already well over 300,000 ) continuing unabated, almost total lack of proper healthcare and good education for the masses, etc.

The present Govt of India has no inkling how to resolve these massive problems, so to divert public attention from them it has to have a scapegoat. This scapegoat is the Muslims, who, like the Jews in the Nazi era, are blamed for all social evils. Muslims are vilified as fanatics, anti-national and terrorists. The Indian media, which has largely been Modified, dutifully obliges by spreading communal hatred.

Propaganda is such a powerful thing that even good peoples minds can be poisoned. For instance, Germans are ordinarily very good people, but during the Nazi era almost the whole German nation went mad, their minds poisoned by Hitler and Goebbels. Similarly, by the communal propaganda and other wicked techniques of the BJP most Hindus have been made Muslim haters in recent years.

Some people deny that BJP is anti-minority, and they refer to Modis statement Sabka saath, sabka vishwas but everyone knows this is hypocrisy and empty rhetoric. BJPs entire politics is based on hatred of minorities, particularly Muslims. BJP is dominated by an organization called the RSS (Rastriya Swayamsevak Sangh ), which is rabidly anti minority ( see the book Bunch of Thoughts by the former RSS leader M.S.Golwalkar). Only by spreading and increasing religious hatred can the BJP thrive.

This world really consists of two worlds, the world of the developed, highly industrialized countries ( North America, Europe, Japan, Australia, New Zealand and China ), and the world of the underdeveloped countries ( which includes India ).

The national objective of India must be to transform and uplift itself into the ranks of the developed countries, for then only can it abolish poverty, unemployment and its other massive problems.

However, this transformation will be opposed tooth and nail by the developed countries, which have an unwritten rule that underdeveloped countries must not be allowed to join the ranks of the developed countries. Why this is so needs to be explained.

Cost of labor is a big chunk of the total cost of production. So if the cost of labor is less the cost of production is less, and one can sell his product at a cheaper price and eliminate his business rival by underselling him i.e. by selling the same quality goods at a cheaper price. There is competition in the market, and one businessman eliminates another not with guns, bombs or tanks but by underselling him.

For instance, after the 1949 Revolution, the Chinese leaders built up a massive industrial base in China. That massive industrial base, coupled with the cheap labor available in China, enabled the Chinese to undersell the whole world in consumer goods. Today the supermarkets of Western countries are packed with Chinese goods, which sell at less than half the price of goods made by Western manufacturers (because the Western labor is expensive). Consequently, many Western industries, which could not face the Chinese competition, had to close down.

Now coming to India, the situation in 1947, when India became independent, was that there were then very few industries and very few engineers. This was because of the policy of the British rulers who did not want India to become an industrialized nation, and wanted to keep it backward and feudal. However, after Independence there was a limited degree of industrialization in India, a heavy industrial base (steel plants etc.) were set up, engineering colleges like IITs were established, etc. The result is that today India is very different from the India of 1947. Today it has all that is required to become a highly industrialized nationa huge pool of technical talent (its IT engineers are largely manning Silicon Valley, and American Universities are full of Indian Professors in Engineering, Science and Mathematics) and immense natural resources.

But if India in fact becomes a highly industrialized country then with its cheap labor it will undersell the Western industrial products. Our labor is even cheaper than Chinese labor, so we will even undersell the Chinese if we get highly industrialized. So, if India gets highly industrialized who will buy the expensive products of the industries of the presently developed countries? Will they not have to close down causing massive unemployment?

India is presently the most developed of the underdeveloped countries, and with correct modern minded leadership it can become a highly developed country in 15-20 years (with modern minded leaders after the Meiji Restoration of 1868 Japan took only this much time to transform itself from a feudal to a highly developed country). But if it does, will it not greatly damage the industries of the developed countries with their expensive labor?

So developed countries will strongly oppose Indias joining the ranks of the developed countries. And how do they do that? By supporting and inciting religious and caste conflicts. In other words, by making Indians fight with each other. I strongly suspect their hidden hand behind the increased religious polarization of Indian society.

[Justice Markandey Katju is former Judge, Supreme Court of India, and former Chairman, Press Council of India. The views expressed are his own.

View original post here:
The religious polarization of India - indica News

Read More...

The fountain of youth? I tested a better anti-ageing program in Switzerland – Metro.co.uk

November 24th, 2019 11:47 pm

In Switzerland we know how to make watches. We also know how to stop time, reads the giant poster in the lobby.

Im at Victoria-Jungfrau Grand Hotel and Spa in Interlaken to sample their Better Aging program and find out if you really can stop the clock and stay looking young or if such ideas are just cuckoo.

The area certainly has a feel of youthful exuberance about it when I arrive Im greeted by paragliders, their colourful canopies drifting down onto the green across from the hotel. During my stay, not a day goes by without seeing the red and yellow wings in death-defying loops.

I can watch them from my room a smart black, brown and gold chamber housing a hard double bed with two single duvets, the traditional Swiss arrangement presumably designed to prevent greedy partners from hogging the covers. Every evening theres a Swiss truffle on my pillow.

The balcony looks out towards the Bernese Alps and the snowy peaks of Jungfrau, which means young woman or maiden. The setting of my anti-ageing quest really couldnt be better.

My journey begins at Nescens Spa, a bright space with lots of natural light, candles and trailing plants.

Spa director Hans-Peter notes down my vitals and bids me stand on a body analysis machine before Im whisked off to a room with personal trainer Brigitte, an intimidatingly fit-looking 49-year-old with a blonde crop.

Its not all bad news I have more muscle than her but I have a lot of body fat (not exactly news to me). She tells me my visceral fat is of particular concern and, among other things, advises me to avoid fruit with a high sugar content such as pineapple and grapes.

The next step is easier to take a de-stressing massage using anti-ageing Nescens oil. This should smoothe the skin and boost cell recapitalisation. The massage is gentler than others Ive had, and quite relaxing, but I cant say my skin looked different afterwards.

The spa does boast outstanding relaxation areas, however. Comfortable couches with mountain views, a smart sauna and the apex of steam rooms with twinkly lights in its starry ceiling, a fountain in middle and a gentle mint scent wafting through the air.

The next morning we come at the ageing issue via exercise with a morning of gentle Pilates. Its run by another uber-fit blonde, Iris.

Then its time for a Better Aging lunch beetroot, goats cheese and orange salad followed by a delicious sea bream with basillicum and vegetables.

Usually guests on the programme stay for at least four days, during which time meals are matched to help them achieve their fitness goals but this cant be easy with a pizzeria, Sapori, as part of the hotel.

The afternoon is dedicated to more exercise a brisk 5km walk with Iris again, through woodland and along the river, emerald with glacier water.

I have the highest hopes for todays anti-ageing treatment a classic silk bliss facial using Sensai products.

My beautician, Nicole, explains how the silk in the range was previously reserved for the Emperor of Japan. Apparently the products can activate your stem cells to help remove wrinkles.

The facial begins with Sensai Silky Purifying Creamy Soap followed by a steamer to open the pores, and some seriously thorough extraction work.

Next came the Silky Purifying Silk Peeling Mask and a mud soap wash and mask, left for six minutes. Finally came four more serums and creams.

My skin looked blotchy but felt very soft afterwards like a velvety cushion. The blotchiness was gone within half an hour, replaced with a glow. The next morning I could feel a spot coming on my neck but my face was plump, smooth and even.

The next day, after a Better Aging breakfast of light bites including tomatos, olives and smoothies, Im back with Brigitte for Nescens Full Body Training. Im cheered by the sight of some pensioners in the class. How hard can it be?

Quite hard, is the answer a full-on but not unbearable 45 minutes of planks, sit ups, star jumps and stretching giant blue elastic bands.

Afterwards I reward myself with a swim in the stunning pool. The main spa has a white, black and gold theme and incredible views.

It also has a lovely outdoor jacuzzi which you swim out to, with bubble beds, jets to massage your feet and back, and a clearer look at the mountains.

At the end of my trip I was more relaxed, my skin felt smoother and I felt fitter. While I may not look younger, as someone approaching 40 Im certainly less stressed about ageing.

Victoria-Jungfrau Grand Hotel and Spa (Picture: Yvette Caster/Metro.co.uk)

Where to stay in Switzerland

Rooms at Victoria-Jungfrau Grand Hotel and Spa cost from 296 per night, with breakfast. Better Aging guests get a 50 per cent discount in high season and 25 per cent discount in low season.

The Better Aging program lasts from four days and costs from 2,499 per person, which includes treatments, personal training and meals.

I flew with Swiss Air from Heathrow to Zrich. Flights cost from 177 return.

To get to the spa I took the train from Zrich airport to Interlaken OST via Bern. Return tickets cost from 116 via Switzerland Tourism. The hotel was about five minutes from the station by taxi.

A Swiss Travel Pass offers unlimited travel throughout the rail, bus and boat network. It includes entrance to 500 museums and costs from 185.

For more on Switzerland visit http://www.MySwitzerland.com.

Where to stay in Heathrow

I stayed at the Radisson Blu Edwardian Heathrow a decadent way to extend the spa experience.

The lobby features an impressive chandelier and theres dark wood and bronzes throughout.

The hotels spa has just had a revamp, and has a relaxation area, cosy sauna, powerful jacuzzi and beautiful blue and gold steam room.

The revamped Radisson spa at the hotel (Picture: Yvette Caster/Metro.co.uk)

I loved the showers you use between each part of the spa. Im sure they would delight fellow Pratchett fans, bringing to mind the Archchancellors bathroom as they do. There were buttons for cold mist, Caribbean storm and waterfall (but thankfully no Old Faithful).

I also tried their chocolate orange massage a thorough, full body treatment. I wasnt overpowered by scent and only really noticed the mild smell of cocoa when it was applied to my chest. It left me feeling refreshed and smelling sweet.

The hotel has two places to dine, Indian restaurant Anayu and Steak and Lobster. My T-bone steak was pleasant, although the blue cheese sauce was a bit bland, while the skinny fries were deliciously seasoned.

I enjoyed chatting to Radissons virtual host, Edward. You can text him anything 24/7 order room service, ask for late checkout and enquire about hotel services. It was like having my own PA.

Rooms at Radisson Blu Edwardian cost from 76.50 per night. They are offering Stay, Park and Fly packages from 102.50 per night, including parking for trips for eight to 15 days.

Go here to see the original:
The fountain of youth? I tested a better anti-ageing program in Switzerland - Metro.co.uk

Read More...

IT will be key to precision medicine’s success in 2020 – MedCity News

November 24th, 2019 11:45 pm

Progress in genomic science has been astronomical over the past few years. In fact, the tipping point that validated the clinical significance of genetic/genomic testing is barely visible in the rearview mirror. As a result, stakeholders ranging from clinicians to regulatory agencies, to professional associations, to payers have begun championing the value that precision medicine delivers in terms of better diagnoses and more effective therapeutic interventions.

For example, in educational materials explaining incidence of dilated cardiomyopathy (DCM), the American Heart Association notes that a full third of DCM patients inherit the condition from their parents or other family members. Germline testing can identify patients with this genetic variant, leading clinicians to a faster diagnosis and earlier treatment. The Food and Drug Administration (FDA) has stated its commitment to approving targeted therapies based on genetic mutations as appropriate. Payers are beginning to issue reimbursement policies to cover the cost of genetic/genomic testing. United Healthcare, for instance, began covering pharmacogenomic panels for patients with anxiety and depression this October.

This leads us to the next great transformation necessitated by precision medicine: implementing the technology infrastructure to govern the ordering and resulting processes inherent to genomics, as well as finding ways to manage the great volumes of data generated by testing.

Precision medicine is already being pursued sporadically across many, if not most, healthcare organizations. Oncologists are likely to be ordering somatic tests to better profile patient tumors so targeted therapies can be delivered. Family practice, behavioral medicine and psychiatric departments are using pharmacogenomics to understand how well (or poorly) patients metabolize specific medications and which might trigger side effects or safety concerns. These insights allow them to prescribe the right treatment at the right dose the first time around instead of spending months on a trial-and-error approach.

Cardiovascular and neurology specialists (among others) order germline tests to help them diagnose, treat and gain new insights into many common conditions such as congestive heart failure, arrhythmias, aneurysms, epilepsy, nerve pain and dementia. Some health systems even order germline tests on all newborns so a full genetic profile is available which can be used throughout the individuals lifetime.

The value of the data being generated through these clinical pockets cannot be understated. It carries information that can be used across a multitude of care settings far into the future to help providers and specialists arrive at more accurate diagnoses faster, and identify the most effective treatment sooner. This, in turn, can help healthcare leaders move the needle to improve quality efforts and optimize revenue while reducing the risk associated with poor outcomes.

To realize full value, however, healthcare organizations must ensure genetic/genomic test results are readily available to clinicians at the point of care and in a vocabulary that makes them meaningful. Unfortunately, few health systems have invested in the IT resources that can make this possible. Currently, test results are ordered in a vacuum and results are often returned in a PDF that will be hard to access. In addition, the information is relayed in a nomenclature unfamiliar to clinicians, so they struggle to understand how to apply the results to specific patient circumstances.

Unless these concerns are addressed, healthcare will simply reenact a mistake made years ago with the advent of electronic health records: valuable data that can immediately and directly impact care will be locked in a silo, unavailable during clinical decision-making.

As the industry heads into 2020, it must make plans and take action to get ahead of this looming problem. Healthcare IT professionals must be brought to the table to help organizations strategize about their precision medicine initiatives. The key to success with this new standard of care is recognition that data generated by genetic/genomic tests can be used endlessly across the enterprise and over the long term as patient conditions change. Organizations must seek out platforms that will consume genomic test results as discrete data and integrate it with patient-specific clinical information. Likewise, the platforms must be made available within existing workflows, so clinicians can leverage it during decision making and can interrogate the data as patient conditions change and genomic science delivers new insights.

Picture: Feodora Chiosea, Getty Images

Original post:
IT will be key to precision medicine's success in 2020 - MedCity News

Read More...

The American College of Rheumatology Adds the Vectra Test to List of Recommended Disease Activity Measures for Rheumatoid Arthritis – GlobeNewswire

November 24th, 2019 11:45 pm

SALT LAKE CITY, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced that the American College of Rheumatology (ACR) has included the Vectra test in its list of recommended disease activity measures for patients with rheumatoid arthritis (RA). The new recommendations were published in the journal Arthritis Care & Research.

The publication titled 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures states that the Vectra test is among 11 disease activity measures that met a minimum standard by categorizing into disease activity states and being feasible for regular clinical use, and that Vectra was one of the five most frequently studied RA disease activity measures among 46 evaluated. Currently, there are more than 35 peer-reviewed Vectra journal publications.

We are excited that the Vectra test has been included the ACRs recommendations for disease activity measures. It will provide physicians with an additional option to evaluate their patients with RA, said Elena Hitraya, M.D., Ph.D., chief medical officer, Myriad Autoimmune. Vectra objectively measures the inflammation associated with RA and can provide valuable information to help clinicians improve treatment decisions and outcomes for patients with RA.

Three out of four rheumatologists have used Vectra and have ordered more than 900,000 tests for their patients. RA is an autoimmune disease that attacks the patients joints and often affects other organ systems, leading to significant morbidity, increased mortality and financial burden. Approximately 60 percent of people with inadequately treated RA are unable to work by a decade after its onset. The American College of Rheumatology estimates that RA affects 1.5 million people in the United States.

About VectraVectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis. Vectra provides unsurpassed ability to predict radiographic progression and can help guide medical management decisions with the goal of improving patient outcomes. Vectra testing is performed at a state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician five to seven days from shipping of the specimen. Physicians can receive test results by fax or the private web portal, VectraView. For more information on Vectra, please visit: http://www.vectrascore.com.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to improving clinician treatment decisions and outcomes for patients with RA; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Here is the original post:
The American College of Rheumatology Adds the Vectra Test to List of Recommended Disease Activity Measures for Rheumatoid Arthritis - GlobeNewswire

Read More...

The Secret To Longevity Could Be Genetics – Medical Daily

November 24th, 2019 11:44 pm

Japan has the worlds oldest population, with 28 percent of all citizens comprising of elderly people above the age of 65. The secret to longevity lies not only in their healthy diet and lifestyle choices, but is influenced by a specific set of genes. Yes, the reason the country has 146 people over the age of 110 (referredto as supercentenarians) is simply good genes. This factor enabled them to stave off cancer and other deadly diseases for more than a century.

A new study conducted by the RIKEN Center for Integrative Medical Science (IMS) and Keio University School of Medicine in Japan sought to understand the genetics behind aging in supercentenarians by analyzing single-cell RNA sequencing.In the paperthat was published in the journal Proceedings of the National Academy of Sciences, the scientists investigated the immune cells of seven supercentenarians and made comparisons to the five subjects with ages between 50 and 80 years.

Researchers looked at 41,208 cells altogether from the elders with ages over 110, and 19,994 cells in the control group. The two cells part of the bodys immune response, which are B-cells and T-cells, were studied.It was found that B-cells had a lower count in the supercentenarians, while T-cells were at the same number in both groups.

However, the major finding was that supercentenarians had more of a particular subset of T-cells, namely CD4 T-cells that are capable of killing harmful cells, which wasonly possible by cytotoxic CD8 T-cells until then. In fact, 80 percent of the T-cells were composed of CD4 markers, whereas 10 to 20 percent of the T-cells had the marker in people of ages between 50 and 80.

The secret to aging may lie in your genes. Photo courtesy of Pexels

Since T-cells with CD8 markers are known to be cytotoxic, this means the CD4 markershad changed to acquire the new function, as per the researchers. This was not the case with the relatively younger subjects, this was the single most unique genetic characteristic of supercentenarians.

"This research shows how single-cell transcription analysis can help us to understand how individuals are more or less susceptible to diseases. CD4-positive cells generally work by generating cytokines, while CD8-positive cells are cytotoxic, and it may be that the combination of these two features allows these individuals to be especially healthy," Piero Carninci, IMS Deputy Director, said.

To understand the unusual phenomenon better, the researchers further studied the cells of two older participants, only to find another interesting fact about the CD4 T-cells: They had descended and multiplied from a single ancestral cell.

"We believe that this type of cells, which are relatively uncommon in most individuals, even young, are useful for fighting against established tumors, and could be important for immunosurveillance. This is exciting as it has given us new insights into how people who live very long lives are able to protect themselves from conditions such as infections and cancer," Carninci added.

Go here to read the rest:
The Secret To Longevity Could Be Genetics - Medical Daily

Read More...

Leveraging AI To Accelerate Precision Health For Longevity – Forbes

November 24th, 2019 11:44 pm

Aging Analytics Agency

Co-authoring this article with me is my colleague Dmitry Kaminskiy, at Deep Knowledge Group.

People over 50 are the fastest growing demographic group worldwide. This creates both opportunities and challenges for the global economy and healthcare systems. The Longevity Industry, which provides products and services for those aged over 50 is becoming a multi-trillion-dollar industry. There are currently 260 companies, 250 investors, 10 non-profits, and 10 research labs in the Longevity Industry in the UK alone. In the next decade, Longevity policies enacted by governments, and changes in the financial industry will transform society. Achieving small but practical results in Longevity distributed at scale will have enormous and multiplicative effects on society. Extending the functional lifespan of humans by just one year will decrease suffering for tens of millions of people and will improve the quality of life for billions of people.

Despite having more potential to increase healthy Longevity in the short term than any other sector, AI for Longevity is an underrepresented sector in the Longevity Industry. AI holds enormous potential to rapidly accelerate the implementation of longevity research and development. To address this, Ageing Research at King's (ARK) in collaboration with the Biogerontology Research Foundation, Deep Knowledge Ventures (at which Dmitry and I are Managing Partners), along with others has established the Longevity AI Consortium at Kings College London. The Consortium will use King's world-leading advances in genetics, AI and ageing research to develop advanced personalized consumer and patient care. The Consortium will help accelerate advances in Longevity using a unique academic-industry focus on preventive and personalized physical, mental and financial health. The establishment of the AI Longevity Consortium and AI Longevity Accelerator at Kings College has the potential to help make the UK the worlds leading AI for Longevity Hub and creates an opportunity for huge advances in Longevity research which will benefit people all around the world.

Over the next few years, the Longevity AI Consortium plans to expand to include centers in Switzerland, Israel, Singapore and the US. This collaborative effort involves sophisticated methods for translating advanced AI for Longevity solutions, along with the development of advanced frameworks and technologies including novel applications of life data for insurance companies, pension funds, healthcare companies, and government bodies. These new technologies and instruments at the forefront of the rising Longevity Financial Industry provide practical applications of preventive medicine and precision health.

Sophisticated Analytical Frameworks for Precision Medicine and Longevity Diagnostics, Prognostics ... [+] and Therapeutic Benchmarking.

The Longevity AI Consortium will serve as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. This represents a paradigm shift from treatment to prevention and a new frontier - from precision medicine to precision health, enabling the UK to become the leading global hub for the application of AI to Longevity and Precision Health. The Longevity AI Consortium plans to dedicate resources to R&D in other niches where the science is ahead of the funding: e.g. microbiome diagnostics and therapeutics, recent advancements and innovations in advanced cosmetics in particular. The Consortium aims to identify novel longevity and healthy ageing biomarkers, accelerate diagnosis of age-related health decline, develop personalised physical, mental and financial health to better implement and promote effective healthy lifestyles for longevity, such as modifying patterns in sleep, nutrition, physical activity, environmental exposure and financial planning.

The Longevity AI Consortium will use sophisticated and multidimensional analytical frameworks developed by Aging Analytics Agency to perform industry benchmarking in precision health and personalized preventive medicine clinics in order to construct the ideal diagnostic, prognostic and therapeutic pipeline using the most advanced market-ready methods and technologies. The Consortium will develop a comprehensive cloud computing platform to enable the development of minimum viable and most comprehensive panels of biomarkers of aging, creating an ecosystem that incentivizes the participation of doctors, clinics, data providers, AI companies and corporate partners, and which enables efficient and streamlined commercialization and clinical implementation of both validated and experimental biomarkers of ageing as a framework for the extension of national Healthy Longevity in the UK.

This mind map provides an overview of the Longevity Industry UK Landscape including 260 companies, ... [+] 250 investors, 10 non-profits, and 10 research labs. (Image source Aging Analytics Agency).

Kings College London is the logical choice of location for the first Longevity AI Consortium, due to their unique combination of resources, departments and technologies for both AI and Longevity. Kings is also an ideal location for the AI Consortium because it has dedicated divisions and resources both for AI and for Longevity. Furthermore, being located in London, it is in an ideal physical location to engage in cross-sector and industry-academic collaboration. The AI Longevity Consortium is currently designing a complementary AI Consortium for Financial Wellness which will utilize financial and behavioural data to develop products and services to enable UK citizens to maintain financial stability, social activity and psychological well-being across extended periods of Healthy Longevity.

Currently there are only three centers in the world actively working to apply AI to precision health for healthy Longevity. These include the US based Buck Institute for Research on Aging, US based Y Combinator, and the US based AI Precision Health Institute (AI-PHI) at the University of Hawaii Cancer Center. Only the AI-PHI has actually succeeded in practice. Now that the Longevity AI Consortium has been established at Kings College London, the UK can immediately leverage its existing resources, including its very well-developed AI industry and its reputation for extremely strong industry, academic, and governmental cooperative initiatives, to become the number one global hub for the application of AI to Longevity and Precision Health.

There are currently four major AI Centres for Healthcare in major industry, academic and metropolitan hubs in the UK, but none of them have a specific focus on Longevity, precision health and preventive medicine. While these centres serve as a precedent and proof-of-concept for the viability of an AI Centre for Longevity, they do not adequately address the need for a leading AI for Longevity R&D nexus within the UK capable of developing leading solutions, products and services that leverage the power of AI to implement practical, real-world product, services and solutions to extend citizens Healthy Longevity.

Sophisticated Analytical Frameworks for Precision Medicine and Longevity Diagnostics, Prognostics ... [+] and Therapeutic Benchmarking

2020 and Beyond

In 2020, following the completion of several key development milestones, the Longevity AI Consortium plans to launch an AI Longevity Accelerator Program that will serve as a much-needed bridge between startups focusing on AI for Longevity research and drug development and major UK investors. While the UKs AI and Longevity industry ecosystems are very developed individually, the number of longevity startups utilizing AI in a major way for their internal R&D is comparatively small. The potential impact presented by the synergy of these two sectors is huge. The UK government has heavily prioritized the separate sectors of AI and Longevity, including both sectors in the top 4 Industrial Strategy Grand Challenges. However, by uniting the AI and Longevity verticals in unique and convergent ways the UK could leverage the nations strengths in these industries to their maximum potential.

AI Longevity Accelerator at Kings College aims to develop an infrastructure to promote increased investments and developments in the AI for Longevity sector to provide AI for Longevity startups with relevant levels of funding. Startups selected for inclusion in the accelerator will also receive mentorship and incubation resources, and will gain access to a global network of experts in the areas of scientific R&D, business development and investment relations. The AI Accelerator will also provide startups with the tools necessary to grow, expand and evolve following their time in the Accelerator, and will equip them with the skills required to develop further through later-stage venture capital and government grants. Longevity companies that prove capable of achieving tangible results may become the next Googles, and investment firms that invest in those companies may become the SoftBanks and Vision Funds of tomorrow. AI holds enormous potential to rapidly accelerate the implementation of Longevity research and development. The establishment of the AI Longevity Consortium and AI Longevity Accelerator at Kings College has the potential to make the UK the worlds leading AI for Longevity Hub and creates an opportunity for huge advances in Longevity research which will benefit billions of people all around the world.

Click the box below for more information on the Longevity AI Consortium.

Click the box below for information on the AI Longevity Accelerator.

Click the box below for in-depth information about the Global Longevity Industry and explore a book that Dmitry and I co-authored: Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History.

See the article here:
Leveraging AI To Accelerate Precision Health For Longevity - Forbes

Read More...

Molecular Forensics World Markets to 2029 – Massive Scope for Adoption of NGS & Capillary Electrophoresis in Emerging Nations – P&T Community

November 24th, 2019 4:46 am

DUBLIN, Nov. 21, 2019 /PRNewswire/ -- The "Global Molecular Forensics Market: Focus on Product, Technology Application, End User, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

This analysis projects the market to grow at a significant CAGR of 9.09% during the forecast period, 2019-2029. The molecular forensics market generated $996.9 million in revenue in 2018, in terms of value.

With the completion of the Human Genome Project (HGP), a new wave of technologies, called next-generation sequencing (NGS) was introduced in the healthcare industry. PCR, and NGS have fundamentally changed genomics research and enabled the scientists to research extensively on the gene variants to specific molecular diagnostics and aided the development of targeted therapeutics depending on the genetic profile of an individual. The completion of the project, subsequently, created platform for the development of precision medicines.

One of the revolutionary breakthroughs which NGS has resulted in is molecular forensics. Molecular forensics involves a detailed study of individual information to identify and characterize the molecular sequences, resulting in target-based identification. This method approach based on biomarker study is perceived to be promising in driving a paradigm shift in the molecular forensics industry, facilitating the elimination of uncertainty pertaining to the trial-and-error method of medications, and certainly eliminating unnecessary healthcare spending. With sequencing being the primitive pivotal step involved in biomarker study and in the field of genetics, the development of the sequencing technologies played a crucial role in the evolution of molecular forensics.

Further remarkable advancements in the field of genomics, proteomics, molecular biology, data analytics, and technical engineering have paved the way for the development of advanced NGS-based technologies, such as SNP and STR sequencing. The impressive research on molecular technologies and biomarkers using NGS has unlocked pathways for the development of momentous various procedures such as mtDNA sequencing.

The growing demand for non-invasive diagnostic procedures enabling genetic profiling has further enhanced the requirement of NGS technologies. Acknowledging the future potential for massive growth in demand for non-invasive diagnostic procedures, several biotechnology companies such as Illumina, Inc., Thermo Fisher Scientific, and Agilent Technologies, Inc. have invested substantially to aid further developments in forensics technologies.

Key Companies in the Molecular Forensics Market

The key manufacturers who have been contributing significantly to the molecular forensics market include Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Promega Corporation, Eurofins Scientific SE, General Electric Company, Merck KGaA, LGC Limited, and Thermo Fisher Scientific Inc. among others.

Key Questions Answered in this Report

Key Topics Covered

Executive Summary

1 Research Scope and Methodology1.1 Scope of the Study1.2 Research Methodology1.3 Data Sources1.4 Assumptions and Limitations1.5 Data and Prediction Modeling

2 Market Overview2.1 Introduction2.2 Molecular Forensics Technologies and Applications2.3 Market Available for Molecular Forensics2.4 Molecular Forensics Technology Trends2.5 Regulations and Compliances

3 Competitive Landscape3.1 Mergers and Acquisitions3.2 Product Launches and Product Updates3.3 Synergistic Activities3.4 Business Expansion Activities and Others

4 Market Dynamics4.1 Overview4.2 Impact Analysis4.3 Market Drivers4.3.1 Augmentation in the Incidences of Crime4.3.2 Growth in the Biomarker Identification Market and Advancements in Molecular Forensics Techniques4.3.3 Technological Advancements in the Field of Computational Biology4.3.4 Significant External Funding for Executing Research and Development Exercises4.4 Market Restraints4.4.1 Lack of High Complexity Testing Centers4.4.2 Expensive Sequencing Procedures and Their Applications in Medical Treatments4.4.3 High Capital Requirement Hampering the Expansion of Global Reach4.5 Market Opportunities4.5.1 Massive Scope for Adoption of NGS and Capillary Electrophoresis in Emerging Nations4.5.2 Technological Advancements in Molecular Techniques and Diagnostic Tests4.5.3 Hybridization of Technologies

5 Global Molecular Forensics Market (By Product)5.1 Overview5.2 Kits and Consumables5.3 Instruments5.4 Software and Other Products

6 Global Molecular Forensics Market (By Technology)6.1 Overview6.2 Polymerase Chain Reaction (PCR)6.2.1 Real-time PCR (q-PCR)6.2.2 Digital PCR (d-PCR)6.3 Capillary Electrophoresis6.4 NGS6.4.1 SNP and STR Sequencing6.4.2 mtDNA Sequencing6.5 Mass Spectrometry6.5.1 MS6.5.2 Tandem MS6.5.3 MS-FTIR6.6 Other Technologies

7 Global Molecular Forensics Market (By Application)7.1 Overview7.2 Radioactive Toxicology7.3 Nucleic Acid Analysis7.4 Forensic Databasing7.5 Microbial Forensics7.6 Other Applications

8 Global Molecular Forensics Market, By End User8.1 Overview8.2 Law Enforcement8.3 Disaster Management8.4 Hospitals and Healthcare Providers8.5 Other End Users

9 Global Molecular Forensics Market, By Region9.1 Overview9.2 North America9.3 Europe9.4 Asia-Pacific9.5 Latin America9.6 Rest-of-the-World

10 Company Profiles10.1 Overview10.2 Agilent Technologies, Inc.10.3 Analytik Jena AG10.4 AS ONE International, Inc.10.5 BioChain Institute Inc.10.6 Bio-Rad Laboratories, Inc.10.7 Eurofins Scientific SE10.8 General Electric Company10.9 Illumina, Inc.10.10 LGC Limited10.11 MACHEREY-NAGEL GmbH & Co KG10.12 Merck KGaA10.13 Promega Corporation10.14 QIAGEN N.V.10.15 Thermo Fisher Scientific Inc.10.16 Verogen, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gfz227

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/molecular-forensics-world-markets-to-2029---massive-scope-for-adoption-of-ngs--capillary-electrophoresis-in-emerging-nations-300962320.html

SOURCE Research and Markets

See the article here:
Molecular Forensics World Markets to 2029 - Massive Scope for Adoption of NGS & Capillary Electrophoresis in Emerging Nations - P&T Community

Read More...

Co-creator of CRISPR lectures about future applications of genome editing technology – Daily Bruin

November 24th, 2019 4:46 am

This post was updated Nov. 20 at 7:47 p.m.

A University of California professor and co-originator of genome editing technology Clustered Regularly Interspaced Short Palindromic Repeats said researchers plan to expand the technology in order to increase human applications at a campus lecture series Thursday.

Jennifer Doudna, a UC Berkeley biochemistry professor, engaged students and the greater UCLA science community during the quarterly Donald J. Cram Distinguished Lecture series.

The Cram lecture series, a quarterly departmental event, invites prominent academics in the field of chemistry to speak about their research. The series is dedicated to Donald J. Cram, who was a Nobel laureate and a chemistry professor at UCLA for over 50 years.

This fall, the series was hosted by UCLA chemistry professor and Cram Chair Patrick Harran.

Scientists use CRISPR technology, formally known as CRISPR-Cas9, to modify DNA sequences and gene functions. Cas9 is a protein that can act like molecular scissor to cut the strands of DNA.

CRISPR is studied and used by students, scientists and researchers to advance progress in the field of gene editing, in medicine and the life sciences.

The UC holds the largest CRISPR patent portfolio in the nation with 16 total patents, according to a UC Berkeley press release.

The United States Patent and Trademark Office granted the UC, along with the University of Vienna and Emmanuelle Charpentier, the director of the Max Planck Institute for Infection Biology, its 16th patent in October.

Doudnas involvement in CRISPR technology began around 2005, when a professor at UC Berkeley, Jill Banfield, invited Doudna to help her with research into the mechanism. From there, Doudna teamed up with Charpentier, who was working with a CRISPR system and its associated protein, Cas9, in 2011.

Doudna is one of the creators of the CRISPR utility for the permanent excision of harmful genes. Doudna said that she developed the idea for the CRISPR technology in 2011 in collaboration with Charpentier.

During the lecture, Doudna detailed how scientists regulate CRISPR enzymes to modify DNA.

CRISPR is a portion of the bacterial genomic sequence that acts as an adaptive immune system, Doudna said.

Bacteria encode the CRISPR system through viral infections, which allows its genome to recognize foreign DNA insertions. These DNA sequences incorporate themselves into the bacterial genome at the CRISPR locus, a genetic database of past infections.

Doudna said this locus was of unique interest to her.

Those sequences, called CRISPR, are transcribed in RNA molecules that provide the zip codes for Cas proteins, allowing them to recognize foreign DNA and cut it up, Doudna said.

Doudna and Charpentier, with the assistance of their team, were able to realize that CRISPR RNA is a 20-nucleotide sequence, which interacts with DNA in a complementary fashion.

This complementarity allows the protein to form a double-stranded break in DNA, necessitating a second RNA tracrRNA to form this functional unit, Doudna said.

And it was (biochemist) Martin Jinek in our lab who figured out that you could combine these two RNAs into a single guide RNA, Doudna said.

From this experiment, Jinek found that single guide RNAs were used by Cas9 to excise DNA at specific sites in a plasmid, a circular piece of bacterial DNA. The revelation from this was that, upon excision, DNA would repair itself in animals and plants, Doudna said.

Doudna said at the end of her talk that the system is becoming increasingly important in the field of medicine, and is currently being used at UCLA, by Donald Kohn, a professor of microbiology, immunology and molecular genetics.

Were within about five years, maybe less, from being able to make, essentially, any change to any genome in any type of cell, Doudna said.

Doudna stressed that this ability to make changes in the genome comes with bioethical responsibility for genome editing in humans.

Fourth-year biochemistry student Jeremy Shek, who attended the event, said although he had done a project that was an offshoot of CRISPR, he had not heard of the progress Doudna discussed.

It is important to be informed on advancements and progress in the field, he added.

Fourth-year bioengineering student Timothy Yu said he came to the lecture to see Doudna in person and get a more solid grasp on the methodology of CRISPR.

Lexi Omholt, a fourth-year microbiology, immunology and molecular genetics student, said that she came to the talk to understand the basis of CRISPR technology.

Jennifer Doudna was one of the reasons I chose my major, Omholt said. At that time, CRISPR came into popular knowledge, and the knockout tool was just coming into use. I am involved in a cancer lab, the Soragni Lab, that uses CRISPR-Cas9 on a regular basis.

See original here:
Co-creator of CRISPR lectures about future applications of genome editing technology - Daily Bruin

Read More...

Biology: Insect populations plummeting, and we should worry – Stock Daily Dish

November 24th, 2019 4:46 am

Steve Rissing

Jan13,2019at4:00AM Jan13,2019at10:44AM

Theres an old joke about what goes through a flys mind as it hits your windshield.

Problem is, not many insects hit windshields anymore, and we might be the butt of that joke.

Biologists have slowly realized our windshields are cleaner these days, even after long highway trips. (I first drove to Death Valley from Indiana to study ant colonies in 1974. I stopped as often for visibility as I did for fuel.)

But the windshield phenomenon, as it is known, suggests something much larger and potentially ominous is underway at the interface of modern humanity and insects. Simply put, there are fewer insects.

Join the conversation at Facebook/columbusdispatch and connect with us on Twitter

Insects are the most ubiquitous group of organisms in the world. They are the largest group of arthropods, and arthropods are 80 percent of all described animal species. Insects play dominant roles in most land-based ecosystems. They pollinate most agricultural crops, cycle nutrients and provide structural complexity and stability to natural food webs.

For some time, studies of single species have suggested that populations of iconic species such as monarch butterflies are crashing. Annual surveys of monarchs wintering in Mexico reveal population declines exceeding 80 percent over the past two decades.

Rusty patched bumblebees once thrived throughout the Midwest, including Ohio. The U.S. Fish & Wildlife Service reports that they have declined 87 percent over the past two decades. They likely live in one-tenth of 1 percent of their former range.

Detecting possible steep declines in insect populations requires long-term, broad-scale studies. Those require funding and professional expertise.

Fortunately, several long-term surveys exist. Publications based on them support what biologists are seeing through their windshields. A New York Times magazine cover story two months ago declared it the Insect Apocalypse.

A 2017 paper in the journal PLOS One reports total insect biomass in German nature reserves declined 76 percent in 27 years. A 2018 paper in the Proceedings of the National Academy of Sciences reports a 63-fold (not percent) reduction in insects captured on sticky traps on the floor of the U.S. El Yunque National Forest in Puerto Rico over the past 40 years. The authors also observed decreases in forest insect-eating birds, frogs and lizards.

Global climate change might account for the demise of insects in tropical areas such as Puerto Rico. The apparent drivers in temperate areas such as Germany are likely more complex. Those drivers include ongoing intensification of agricultural practices and pesticide use.

Making the apparent insect collapse even worse, a recent American Entomologist paper documents the disappearance of insects from college introductory biology textbooks. The authors found that a century ago, textbooks devoted 8.8 percent of their pages to insects and their interactions with humans. Textbooks published since 2000 devote less than 0.6 percent of their pages to insects, with even less emphasis on human-insect interactions.

Topics such as modern molecular genetics, exciting to instructors who adopt textbooks, crowd out topics possibly more relevant to students, especially in general education courses.

As humanity disrupts and reduces our planets natural systems, responsible citizens and the policymakers they elect eventually will need to develop policies that mitigate and respond to changes such as massive losses of insects.

This is no time to drive blindly into that future, even if our windshields are eerily clean.

Steve Rissingis a biology professor at Ohio State University.

steverissing

More here:
Biology: Insect populations plummeting, and we should worry - Stock Daily Dish

Read More...

Page 820«..1020..819820821822..830840..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick